The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 12, 2014, Pages 1689-1695

  Devillier, Philippe ^a,b   Chassany, O ^c,d   Vicaut, E ^e   De Beaumont, O ^f   Robin, B ^f   Dreyfus, J F ^b   Bousquet, P J ^g  

^a UPRES EA 220   (France)

^b FOCH HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL FERNAND WIDAL   (France)

^f Stallergenes SA   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Allergic rhinoconjunctivitis; Minimally important difference; Symptom score

Indexed keywords

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; AGE DISTRIBUTION; ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT TOOL; FEMALE; GLOBAL RATING OF CHANGE SCALE; GRASS POLLEN; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; RHINOCONJUNCTIVITIS; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RHINOCONJUNCTIVITIS TOTAL SYMPTOM SCORE; SCHOOL CHILD; AGED; CLINICAL TRIAL; COMORBIDITY; CONJUNCTIVITIS, ALLERGIC; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; POLLEN; PRESCHOOL CHILD; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; RHINITIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ALLERGEN;

ADOLESCENT; ADULT; AGED; ALLERGENS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CONJUNCTIVITIS, ALLERGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; POLLEN; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84909630767     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12518     Document Type: Article

References (36)

1. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391-1396.
2. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;9:S742-S749.
3. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-S334.
4. EMA. European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. 2008.
5. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:163-169.
6. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007;62:367-372.
7. Numminen J, Ahtinen M, Huhtala H, Rautiainen M. Comparison of rhinometric measurements methods in intranasal pathology. Rhinology 2003;41:65-68.
8. Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003;91:105-114.
9. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998;101:163-170.
10. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-423.
11. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999;104:364-369.
12. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-109.
13. Bousquet PJ, Combescure C, Klossek JM, Daures JP, Bousquet J. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol 2009;123:1349-1354.
14. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy 2013;43:881-888.
15. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98:843-845.
16. Meltzer EO, Schatz M, Nathan R, Garris C, Stanford RH, Kosinski M. Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. J Allergy Clin Immunol 2013;131:379-386.
17. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-324.
18. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59.
19. FDA. Guidance for industry. Allergic rhinitis: clinical development programs for drug products. Center for Drug Evaluation and Research. 2000:2718.
20. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy 2010;40:242-250.
21. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-87.
22. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-1618.
23. Sloan JA, Vargas-Chanes D, Kamath CC, Sargent DJ, Novotny PJ, Atherton P. Detecting worms, ducks, and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integr Med 2003;1:41-47.
24. Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther 2012;20:160-166.
25. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57:898-910.
26. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
27. Turner D, Schunemann HJ, Griffith LE, Beaton DE, Griffiths AM, Critch JN et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010;63:28-36.
28. Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santanello NC et al. Interpreting and reporting results based on patient-reported outcomes. Value Health 2007;10(Suppl 2):S116-S124.
29. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
30. Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541-546.
31. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124:719-723.
32. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting G. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383.
33. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Resp J 2010;36:1410-1416.
34. Le QA, Doctor JN, Zoellner LA, Feeny NC. Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT). Health Qual Life Outcomes 2013;11:59.
35. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Resp J 2002;19:398-404.
36. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132-140.